Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (NASDAQ: LTRN) reported updated Phase 2 HARMONIC™ data for LP-300 in EGFR Exon 21 L858R-mutant NSCLC after TKI therapy. L858R patients treated through up to six cycles reached 8.9-month median PFS (8.4 months overall; n=15), with >70% tumor reduction in evaluable patients and a 77% clinical benefit rate.
Across 31 patients, LP-300 added no clinically meaningful toxicity beyond carboplatin/pemetrexed, with low serious treatment-related events in cross-trial comparisons versus amivantamab regimens. An FDA-cleared amendment extends LP-300 dosing to eight cycles, and enrollment is concentrating on L858R patients. Lantern is using these data for partnering discussions at ASCO 2026.
Lantern Pharma (NASDAQ: LTRN) reported a successful FDA Type C interaction for its Phase 2 HARMONIC™ trial of LP-300 in never-smokers with advanced NSCLC.
The FDA raised no objections to protocol changes: enriching for EGFR exon 21 L858R patients, extending LP-300 dosing to eight cycles, and moving to a single-arm, enriched design.
Preliminary data show an 8.3‑month median progression-free survival in L858R patients and an early U.S. cohort with 86% clinical benefit and 43% objective response, with one complete response lasting over two years.
Lantern Pharma (NASDAQ:LTRN) reported Q1 2026 results marked by cost reductions, pipeline progress, and new AI initiatives. R&D spend fell 47% year-over-year and Q1 net loss declined 27% while multiple oncology programs advanced.
Cash, equivalents, and marketable securities were $6.3M on March 31, 2026; combined with about $4.4M in May 14 financing proceeds, pro forma liquidity is expected to fund operations into the middle of Q1 2027. Lantern launched its commercial multi-agentic AI platform withZeta.ai, expanded predictBBB.ai into a broader molecular intelligence service, obtained a successful FDA Type C meeting outcome for the LP-300 HARMONIC trial, and received FDA IND clearance for a pediatric CNS cancer trial via subsidiary Starlight Therapeutics. Lantern also plans to separate withZeta.ai into an independent entity under CEO Panna Sharma.
Lantern Pharma (NASDAQ: LTRN) closed a registered direct offering of 2,135,923 common shares (or pre-funded warrants) at $2.06 per share, raising approximately $4.4 million in gross proceeds, before fees.
In a concurrent private placement, Lantern issued unregistered warrants for up to 2,135,923 shares at $2.27, potentially adding about $4.85 million in gross proceeds if fully exercised. Proceeds are intended for working capital and general corporate purposes.
Lantern Pharma (NASDAQ: LTRN) entered a definitive agreement for a registered direct offering of 2,135,923 common shares or pre-funded warrants at $2.06 per share, raising about $4.4 million in gross proceeds.
Concurrent private warrants for up to 2,135,923 shares at $2.27 could add $4.85 million. Lantern also plans an independent AI entity based on its withZeta.ai platform.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, plans to report its Q1 2026 operating and financial results on Friday, May 15, 2026.
The press release will cover financial results for the quarter ended March 31, 2026 and provide updates on clinical trials and development of the company’s AI platforms.
Lantern Pharma (NASDAQ: LTRN) unveiled a development roadmap for withZeta.ai on May 7, 2026, adding ZetaSwarm™ (multi-agent swarm intelligence), ZetaOmics™ (real-time multi-omic bioinformatics), and enterprise-grade features. The platform is commercially available via subscription and is presented as a non-dilutive revenue stream.
Planned capabilities include 34-tool integration, real-time cohort analyses, coordinated specialist agents, org-level accounts, audit logs, private knowledge bases, and institutional deployment features.
Lantern Pharma (NASDAQ: LTRN) expanded predictBBB.ai into a real-time Large Quantitative Model (LQM) delivered as a web service for small-molecule developability profiling. By submitting a single SMILES string users get a 360-degree profile in seconds across 99 molecular features, with five algorithms ranking in the top 12 on the Therapeutic Data Commons leaderboard. The LQM is integrated into withZeta.ai, supports high-throughput screening, and is offered under a planned subscription roadmap with API access in development; Lantern is inviting early collaboration with pharma partners.
Lantern Pharma (NASDAQ: LTRN) will publicly demonstrate withZeta.ai, its multi‑agentic AI co‑scientist platform, on April 30, 2026 with two live sessions at 8:30 AM ET and 4:30 PM ET.
The platform, publicly shown after debuts at Nasdaq MarketSite and AACR 2026, executes real‑time multi‑database research workflows and offers subscription tiers aimed at rare cancer research and commercial users.
Lantern Pharma (NASDAQ: LTRN) scheduled a mid‑May 2026 Type C meeting with the FDA to seek protocol amendments to its Phase 2 HARMONIC trial of LP-300. Emerging data (cutoff April 13, 2026) show an 8.3‑month mPFS in EGFR Exon 21 L858R patients (n=16) with no added toxicity versus chemotherapy.
Lantern proposes focusing enrollment on L858R, converting to a Simon two‑stage single‑arm Phase 2, and increasing LP-300 cycles from 6 to 8 to further evaluate durability and safety.